FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Comparision between C2C Advanced Systems IPO and Onyx Biotec IPO.
C2C Advanced Systems IPO is a SME Book Built Issue IPO proposed to list at NSE SME while Onyx Biotec IPO is a SME Book Built Issue proposed to list at NSE SME.
C2C Advanced Systems IPO | Onyx Biotec IPO | |
---|---|---|
Logo | ||
Issue Category | SME | SME |
Issue Type | IPO | IPO |
Process Type | Book Built Issue | Book Built Issue |
Listing At | NSE SME | NSE SME |
Lead Managers | Mark Corporate Advisors Private Limited Beeline Capital Advisors Pvt Ltd |
Horizon Management Private Limited |
Registrar | Link Intime India Private Ltd | Mas Services Limited |
Market Maker | Spread X Securities Private Limited | Giriraj Stock Broking Private Limited |
DRHP | DRHP | DRHP |
RHP | RHP | RHP |
Anchor Investor | Anchor Investor | |
IPO Allotment URL |
The total issue size of C2C Advanced Systems IPO is up to ₹99.07 Cr whereas the issue size of the Onyx Biotec IPO is up to ₹29.34 Cr. The final issue price of C2C Advanced Systems IPO is and of Onyx Biotec IPO is ₹61.00 per share.
C2C Advanced Systems IPO | Onyx Biotec IPO | |
---|---|---|
Face Value | ₹10 per share | ₹10 per share |
Issue Price (Lower) | ₹214.00 per share | ₹58.00 per share |
Issue Price (Upper) | ₹226.00 per share | ₹61.00 per share |
Issue Price (Final) | ₹61.00 per share | |
Discount (Retail) | ||
Discount (Employee) | ||
Market Lot Size | 600 shares | 2000 shares |
Fresh Issue Size | 43,83,600 shares | 48,10,000 shares |
Fresh Issue Size (Amount) | up to ₹99.07 Cr | up to ₹29.34 Cr |
OFS Issue Size | ||
OFS Issue Size (Amount) | ||
Issue Size Total | 43,83,600 shares | 48,10,000 shares |
Issue Size Total (Amount) | up to ₹99.07 Cr | up to ₹29.34 Cr |
C2C Advanced Systems IPO opens on Nov 22, 2024, while Onyx Biotec IPO opens on Nov 13, 2024. The closing date of C2C Advanced Systems IPO and Onyx Biotec IPO is Nov 26, 2024, and Nov 18, 2024, respectively.
C2C Advanced Systems IPO | Onyx Biotec IPO | |
---|---|---|
Anchor Bid Date | Nov 21, 2024 | Nov 12, 2024 |
Issue Open | Nov 22, 2024 | Nov 13, 2024 |
Issue Close | Nov 26, 2024 | Nov 18, 2024 |
Basis Of Allotment (Tentative) | Nov 27, 2024 | Nov 19, 2024 |
Initiation of Refunds (Tentative) | Nov 28, 2024 | Nov 20, 2024 |
Credit of Share (Tentative) | Nov 28, 2024 | Nov 20, 2024 |
Listing date (Tentative) | Nov 29, 2024 | Nov 21, 2024 |
Anchor Lockin End date 1 | Dec 27, 2024 | Dec 19, 2024 |
Anchor Lockin End date 2 | Feb 25, 2025 | Feb 17, 2025 |
C2C Advanced Systems IPO P/E ratio is 22.56, as compared to Onyx Biotec IPO P/E ratio of 26.81.
C2C Advanced Systems IPO | Onyx Biotec IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial | C2C Advanced Systems Limited Financial Information (Restated)C2C Advanced Systems Limited's revenue increased by 412% and profit after tax (PAT) rose by 327% between the financial year ending with March 31, 2024 and March 31, 2023.
|
Onyx Biotec Limited Financial Information (Restated)Onyx Biotec Limited's revenue increased by 35.99% and profit after tax (PAT) rose by 64.35% between the financial year ending with March 31, 2024 and March 31, 2023.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Pre-Issue) | 56.52% | 88.60% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Post-Issue) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
P/E Ratio | 22.56 | 26.81 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Market Cap | ₹376.09 Cr. | ₹110.61 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROE | 4.99%% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROCE | 3.71%% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt/Equity | 0.15 | 1.21 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EPS | ₹10.02 | ₹2.28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RoNW | 11.29%% | 4.99%% |
In the C2C Advanced Systems IPO retail investors (RII) are offered while in Onyx Biotec IPO retail investors are offered . Qualified institutional buyers (QIB) are offered in C2C Advanced Systems IPO and 9,12,000 shares in Onyx Biotec IPO.
C2C Advanced Systems IPO | Onyx Biotec IPO | |
---|---|---|
Anchor Investor Reserveration | 12,49,200 shares | 13,66,000 shares |
Market Maker Reserveration | 2,19,600 shares | 2,44,000 shares |
QIB | 9,12,000 shares | |
NII | 6,88,000 shares | |
RII | 16,00,000 shares | |
Employee | 0 shares | |
Others | ||
Total | 32,00,000 shares |
C2C Advanced Systems IPO subscribed in total, whereas Onyx Biotec IPO subscribed 9.95x.
C2C Advanced Systems IPO | Onyx Biotec IPO | |
---|---|---|
QIB (times) | 0.00x | |
NII (times) | 8.15x | |
Big NII (times) | ||
Small NII (times) | ||
RII (times) | 16.40x | |
Employee (times) | ||
Other (times) | ||
Total (times) | 9.95x |
Add a public comment...
Rs 0 Account Opening Fee
Free Eq Delivery & MF
Flat ₹20 Per Trade in F&O
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|